- Home
- LAZ vs APLS Comparison
LAZ vs APLS Comparison
Compare LAZ & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZ
- APLS
- Stock Information
- Founded
- LAZ 1848
- APLS 2009
- Country
- LAZ United States
- APLS United States
- Employees
- LAZ N/A
- APLS N/A
- Industry
- LAZ Investment Managers
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- LAZ Finance
- APLS Health Care
- Exchange
- LAZ Nasdaq
- APLS Nasdaq
- Market Cap
- LAZ 4.1B
- APLS 2.3B
- IPO Year
- LAZ 2005
- APLS 2017
- Fundamental
- Price
- LAZ $43.02
- APLS $17.81
- Analyst Decision
- LAZ Hold
- APLS Buy
- Analyst Count
- LAZ 7
- APLS 18
- Target Price
- LAZ $46.83
- APLS $39.71
- AVG Volume (30 Days)
- LAZ 1.2M
- APLS 2.7M
- Earning Date
- LAZ 04-25-2025
- APLS 05-07-2025
- Dividend Yield
- LAZ 4.65%
- APLS N/A
- EPS Growth
- LAZ N/A
- APLS N/A
- EPS
- LAZ 2.87
- APLS N/A
- Revenue
- LAZ $2,939,019,000.00
- APLS $775,839,000.00
- Revenue This Year
- LAZ N/A
- APLS $12.25
- Revenue Next Year
- LAZ $12.53
- APLS $21.08
- P/E Ratio
- LAZ $14.96
- APLS N/A
- Revenue Growth
- LAZ 7.18
- APLS 48.04
- 52 Week Low
- LAZ $31.97
- APLS $16.65
- 52 Week High
- LAZ $61.14
- APLS $43.99
- Technical
- Relative Strength Index (RSI)
- LAZ 59.59
- APLS 36.61
- Support Level
- LAZ $39.71
- APLS $16.65
- Resistance Level
- LAZ $41.55
- APLS $20.75
- Average True Range (ATR)
- LAZ 1.66
- APLS 1.11
- MACD
- LAZ 0.85
- APLS 0.24
- Stochastic Oscillator
- LAZ 94.01
- APLS 28.29
About LAZ Lazard Inc.
Lazard has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.